A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabetes Mellitus (T2DM)

NCT02072096 on ClinicalTrials.gov · last registry update 2019-10-09

Stopped early, having planned 192 participants. Completed October 2015. liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: TERMINATED
Phase: P4
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: Eli Lilly and Company
Sponsor type: Industry
Enrollment: 192
Started: 2014-02
Primary completion: 2015-10 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Percentage of Participants Achieving and Maintaining Individualized Glycated Hemoglobin A1c (HbA1c) Targets Without Clinically Significant Hypoglycemia

Conditions studied

Diabetes Mellitus, Type 2

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.